US Lawmakers Sound Alarm Over China’s Growing Dominance in Pharma Supply Chain
Key Takeaways
- The House Select Committee on China has warned that Beijing is executing a long-term strategy to dominate the global pharmaceutical market, mirroring its tactics in the rare earth and EV sectors.
- With China's drug and medical device revenue projected to reach $2.1 trillion by 2030, US officials are calling for urgent action to reduce reliance on Chinese-made active pharmaceutical ingredients.
Mentioned
Key Intelligence
Key Facts
- 1China's pharmaceutical and medical device revenue is projected to exceed $2.1 trillion by 2030.
- 2The Chinese pharmaceutical industry is expected to grow by 50% between 2024 and 2030.
- 3A 2025 Brookings Institution report estimates China provides 25% of the drug volume sold in the US.
- 4Lawmakers compare China's pharma strategy to its dominance in rare earths, EVs, and semiconductors.
- 5The House Select Committee on China warns of a deliberate strategy to 'own the whole stack' of the supply chain.
Who's Affected
Analysis
The United States is facing a critical inflection point regarding its pharmaceutical sovereignty, as recent congressional testimony highlights a deepening dependence on Chinese manufacturing for both essential generic medicines and future biotechnological innovations. During a high-profile hearing titled From the Science Lab to the Medicine Cabinet: How China is Cornering the Market on Our Medicines, members of the House Select Committee on China argued that Beijing is systematically applying a proven economic playbook to the life sciences sector. This strategy, which has already seen China secure dominant positions in rare earth minerals, semiconductors, and electric vehicle batteries, involves heavy state subsidies and a deliberate move up the value chain to control the entire pharmaceutical stack.
John Moolenaar, chair of the committee, emphasized that this is not merely a matter of trade imbalance but a fundamental national security risk. The concern extends beyond the current supply of active pharmaceutical ingredients (APIs) to the cutting-edge biotech pipeline that will define medical leadership in the coming decades. By subsidizing domestic firms and leveraging its massive internal market, China is positioned to dictate the terms of global drug availability. This mirrors the aggressive expansion seen in other critical technologies where China initially served as a low-cost manufacturer before evolving into a dominant global supplier that can exert geopolitical leverage through supply chain control.
Projections from UBS suggest that China’s pharmaceutical and medical device industries are on track to generate more than $2.1 trillion in revenue by 2030.
Market data underscores the scale of this shift. Projections from UBS suggest that China’s pharmaceutical and medical device industries are on track to generate more than $2.1 trillion in revenue by 2030. This growth is fueled by a domestic aging population and a concerted global expansion effort, with industry revenue expected to rise by 50 percent between 2024 and 2030. For US policymakers, the most alarming aspect is the lack of transparency and the high degree of concentration in the production of APIs—the essential components that give drugs their intended health effects. While some experts, including Marta Wosinska, suggest that certain statistics may overstate the absolute volume of US reliance, the strategic vulnerability remains high, particularly for essential antibiotics and chronic care medications.
What to Watch
A 2025 report from the Brookings Institution estimated that Chinese-made APIs account for roughly one-quarter of the drug volume sold in the United States. However, the qualitative dependence may be even higher, as many global manufacturers in third-party countries like India still rely on Chinese precursors to synthesize their own products. Representative Neal Dunn noted that China’s strategy involves moving up the supply chain until they own the entire ecosystem, effectively making it impossible for Western firms to compete on price without similar levels of government intervention. This has led to a hollowing out of domestic US manufacturing capabilities for generic drugs, leaving the healthcare system vulnerable to potential trade disruptions or quality control issues originating overseas.
Looking forward, the pharmaceutical industry should anticipate increased legislative pressure to diversify supply chains and potentially reshore API production. We are likely to see proposals for new tax incentives or domestic procurement requirements aimed at reducing the 'China-plus-one' strategy's reliance on Beijing. However, the transition will be fraught with challenges, as the cost advantages currently enjoyed by Chinese producers are significant. For biotech and pharma companies, the immediate priority will be conducting deep-tier supply chain audits to identify hidden dependencies on Chinese precursors. As the geopolitical landscape shifts, the ability to demonstrate supply chain resilience may soon become as important to investors and regulators as the clinical efficacy of the drugs themselves.
From the Network
How we covered this story
Every story in our biotech coverage is assembled from multiple primary sources, cross-referenced for factual consistency, and scored along three independent dimensions: sentiment, operational impact, and source-cluster confidence. Single-source rumors and unverifiable claims do not pass our editorial gate. When a story shows "Verified by N sources" with N≥2, the development is independently corroborated; when N=1, we mark it explicitly so readers can weigh the signal accordingly.
Impact scoring uses a 1-10 scale weighted toward regulatory, financial, and operational consequence rather than coverage volume. A topic that runs in every outlet but moves no real decisions ranks lower than a niche regulatory filing that reshapes how operators in the biotech space have to behave. Read our full methodology for the scoring rubric, our glossary for term definitions, and our trends index for the longitudinal view across the beat.
| Signal on this page | What it tells you |
|---|---|
| Verified by N sources | Independent corroboration count. N≥2 is our confidence floor; N=1 is marked explicitly. |
| Impact score (1-10) | Regulatory + financial + operational weight. 8+ signals an experienced-operator action item. |
| Sentiment | Five-tier classification trained on labeled biotech-specific corpora. |
| Timeline | Where applicable, the related-events sequence that contextualizes today's development. |